Home Newsletter Honored Guests Blog About Us Work With Us Sponsor & Advertise Be a Guest The Production Suite Get the Briefing

Open Door Salon

Anne Herold Li

Anne Herold Li

Shareholder & NY Managing Partner, Brownstein Hyatt Farber Schreck | Co-Chair, Life Sciences Practice

Anne Herold Li is a shareholder at Brownstein Hyatt Farber Schreck, where she serves as managing partner of the firm’s New York office and co-chairs its Life Sciences practice. A first-chair trial lawyer and member of a Chambers-ranked patent team, she focuses on intellectual property and litigation in the life-sciences industry. She trained and worked as an epidemiologist before becoming a lawyer, and holds her law degree from Fordham University School of Law.

Her practice spans patent litigation, intellectual-property strategy, and the structuring of complex life-sciences transactions, work that places her at the center of the trade, tariff, and national-security questions now reshaping the industry. At the time of her appearance she was working on the Supreme Court cases over the administration’s tariffs, on behalf of a range of clients.

Herold Li appeared on Open Door Salon alongside Colin Zick, a partner at Foley Hoag, for a wide-ranging conversation on the legal and regulatory forces reshaping life sciences. She walked through what a tariff reversal would mean for the more than 300,000 companies that had paid them, the revival of the Bayh-Dole Act as a lever to force domestic manufacturing of federally funded inventions, and how dealmakers can structure China-linked biotech transactions around the returning Biosecure Act.

Her throughline was practical: the legal landscape is shifting on many fronts at once, but each shift creates a structuring or positioning question that a well-advised company can get ahead of rather than be caught by.

On Open Door Salon

“Everything Everywhere All at Once”
Colin Zick & Anne Herold Li · February 3, 2026

Episode page & show notes on Open Door Salon

“Over 300,000 companies and people who have paid these tariffs are going to have to file to get their money back.”Anne Herold Li, on Open Door Salon (on the Supreme Court tariff cases she is litigating)
“If you're going to use government-funded patents, we are allowed to make you comply with what you agreed to when you got the funding or licensed the patents, which is: do it here.”Anne Herold Li, on Open Door Salon (on reviving Bayh-Dole to force domestic manufacturing)
“With the Biosecure Act, implementation is everything… there's also a way to structure your deals, because biosecure is really looking at not letting money flow back to the Chinese government after the five-year implementation period.”Anne Herold Li, on Open Door Salon (on structuring China biotech deals around the Biosecure Act)

In this episode

  • The Supreme Court tariff cases and the IEEPA question
  • 300,000+ companies filing to get tariff payments back
  • Reviving the Bayh-Dole Act to force domestic manufacturing
  • A floated "patent tax" on federally funded inventions
  • Onshoring in many flavors, not just tariffs
  • Structuring China-linked biotech deals around Biosecure
  • The five-year Biosecure implementation window
  • Getting ahead of the next disruption

Topics

Intellectual PropertyPatent LitigationLife Sciences LawTrade & TariffsBayh-Dole ActBiosecure ActDeal StructuringRegulatory StrategyBiotech M&ALife Sciences Policy

Watch on Open Door Salon

Everything Everywhere All at Once | Colin Zick & Anne Herold Li

Open Door Salon brings life-sciences leaders into candid conversation. Every Monday, the week's takeaways land in your inbox.

Subscribe on Substack →
The Briefing

Need the life-sciences signal but short on time?

Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.